Memo To File: FDA Managers Rebut Rogue Reviewer
This article was originally published in RPM Report
Executive Summary
Here is a May 14 memo “to the file” signed by ODE I Director Ellis Unger, Deputy Director Robert Temple and Cardio-Renal Drug Products Division Director Norman Stockbridge, responding to the “unsolicited” reviews of Avandia submitted by cardio-renal division reviewer Thomas Marciniak. It was included in the briefing documents provided to the FDA advisory committee ahead of a June 5-6 meeting.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.
Cost-Based Pricing: The Real Threat Hiding In Latest US Drug Price Headlines
Bernie Sanders is back at it, getting headlines for demanding immediate price cuts to Novo’s blockbuster GLP-1 brands. But behind the familiar rhetoric is a newer threat: academic research on cost-based pricing that could one day feed into the emerging Medicare ‘negotiation’ system.